Radiation plus immunotherapy: a one-two punch against metastatic cancer?
NCT ID NCT02843165
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding stereotactic body radiation therapy (SBRT) to standard checkpoint immunotherapy improves tumor response in 106 people with advanced metastatic cancer. Participants received either immunotherapy alone or immunotherapy plus SBRT to one tumor site. The goal was to see if the combination leads to more tumor shrinkage and longer time without cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Checkpoint blockade immunotherapy (anti-CTLA-4 and anti-PD-1/PD-L1 antibodies) plus stereotactic body radiation therapy (SBRT)
What this could lead to
If it works, this combination could improve tumor shrinkage and delay cancer progression in people with advanced metastatic cancer.
What could go wrong
This is a phase 2 trial with only 106 participants, so results may not apply to everyone. Adding radiation to immunotherapy can increase side effects like inflammation or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States